Company intelligence / Profile preview

ViaLase

Aliso Viejo, California, United Statesvialase.com ↗

Ownership: Private
Development stage: Clinical

Overview

ViaLase has developed a first-in-class femtosecond laser system for noninvasive treatment of primary open-angle glaucoma. Early human studies showed a mean intraocular pressure reduction of over 34% at two years with no serious adverse events. The pivotal VIA‑002 trial enrolled 152 patients and compares FLigHT to selective laser trabeculoplasty; results are pending but early data support safety and efficacy. The device received CE Mark approval in July/August 2024, enabling initial commercialization in select European markets later this year.

Therapeutic areas: Ophthalmology
Modalities: Device (Femtosecond laser system)Non-pharmacological therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

ViaLuxe Laser System

Clinical

Indications: Primary open angle glaucoma

Partnerships

Teleon Surgical (Germany & Austria)Global Surgical Service (Spain & Portugal)

Beyond the preview

Go deeper on ViaLase.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViaLase.

Explore the full profile